EA200100284A1 - Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени - Google Patents

Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени

Info

Publication number
EA200100284A1
EA200100284A1 EA200100284A EA200100284A EA200100284A1 EA 200100284 A1 EA200100284 A1 EA 200100284A1 EA 200100284 A EA200100284 A EA 200100284A EA 200100284 A EA200100284 A EA 200100284A EA 200100284 A1 EA200100284 A1 EA 200100284A1
Authority
EA
Eurasian Patent Office
Prior art keywords
migraine
methoclopramid
agonists
receptors
treatment
Prior art date
Application number
EA200100284A
Other languages
English (en)
Inventor
Джордж Гарри Сандз
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200100284A1 publication Critical patent/EA200100284A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Настоящее изобретение относится к способу лечения мигрени у млекопитающего, включая человека, путем введения этому млекопитающему агониста 5HT-рецепторов, и в частности элетриптана, в комбинации с метоклопрамидом. Оно также относится к фармацевтическим композициям, содержащим фармацевтически приемлемый носитель, агонист 5HT-рецепторов и метоклопрамид.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100284A 1998-10-30 1999-10-18 Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени EA200100284A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10632898P 1998-10-30 1998-10-30
PCT/IB1999/001694 WO2000025778A1 (en) 1998-10-30 1999-10-18 5ht1 receptor agonists and metoclopramide for the treatment of migraine

Publications (1)

Publication Number Publication Date
EA200100284A1 true EA200100284A1 (ru) 2001-10-22

Family

ID=22310818

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100284A EA200100284A1 (ru) 1998-10-30 1999-10-18 Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени

Country Status (34)

Country Link
US (2) US6255334B1 (ru)
EP (1) EP1126840A1 (ru)
JP (1) JP2002528497A (ru)
KR (1) KR20010089363A (ru)
CN (1) CN1325304A (ru)
AP (1) AP2001002129A0 (ru)
AR (1) AR019246A1 (ru)
AU (1) AU5994799A (ru)
BG (1) BG105534A (ru)
BR (1) BR9914901A (ru)
CA (1) CA2348543A1 (ru)
CO (1) CO4950530A1 (ru)
CZ (1) CZ20011468A3 (ru)
EA (1) EA200100284A1 (ru)
EE (1) EE200100243A (ru)
GT (1) GT199900189A (ru)
HK (1) HK1040929A1 (ru)
HR (1) HRP20010298A2 (ru)
HU (1) HUP0104696A3 (ru)
ID (1) ID28291A (ru)
IL (1) IL141957A0 (ru)
IS (1) IS5898A (ru)
MA (1) MA26702A1 (ru)
NO (1) NO20012013L (ru)
OA (1) OA11669A (ru)
PA (1) PA8484801A1 (ru)
PE (1) PE20001284A1 (ru)
PL (1) PL347541A1 (ru)
SK (1) SK5522001A3 (ru)
TN (1) TNSN99203A1 (ru)
TR (1) TR200101174T2 (ru)
TW (1) TW524692B (ru)
WO (1) WO2000025778A1 (ru)
ZA (1) ZA200103322B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
ES2316571T3 (es) * 2001-05-24 2009-04-16 Alexza Pharmaceuticals, Inc. Administracion de alprazolam, estazolam, midazolam o triazolam a traves de una via inhalatoria.
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
WO2002094242A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
WO2003041693A1 (en) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
WO2003057188A1 (en) 2001-11-21 2003-07-17 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
US8003080B2 (en) 2002-05-13 2011-08-23 Alexza Pharmaceuticals, Inc. Delivery of drug amines through an inhalation route
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
CN101371843B (zh) 2002-11-26 2012-09-26 艾利斯达医药品公司 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2005123043A2 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US7375219B2 (en) * 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
TW200808780A (en) * 2006-04-13 2008-02-16 Neuraxon Inc 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2009064505A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
BRPI0820632A2 (pt) * 2007-11-16 2015-06-16 Neuraxon Inc Compostos de indol e métodos para tratamento de dor visceral
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
IL127956A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
GB9709739D0 (en) 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation

Also Published As

Publication number Publication date
GT199900189A (es) 2001-04-21
PE20001284A1 (es) 2000-11-22
TW524692B (en) 2003-03-21
AP2001002129A0 (en) 2001-06-30
CN1325304A (zh) 2001-12-05
BG105534A (en) 2001-12-29
EE200100243A (et) 2002-12-16
HK1040929A1 (zh) 2002-06-28
OA11669A (en) 2005-01-05
NO20012013D0 (no) 2001-04-24
AR019246A1 (es) 2001-12-26
AU5994799A (en) 2000-05-22
KR20010089363A (ko) 2001-10-06
US6255334B1 (en) 2001-07-03
PL347541A1 (en) 2002-04-08
IL141957A0 (en) 2002-03-10
CO4950530A1 (es) 2000-09-01
PA8484801A1 (es) 2000-09-29
JP2002528497A (ja) 2002-09-03
IS5898A (is) 2001-03-16
HUP0104696A2 (hu) 2002-05-29
WO2000025778A1 (en) 2000-05-11
CZ20011468A3 (cs) 2002-04-17
HRP20010298A2 (en) 2002-06-30
EP1126840A1 (en) 2001-08-29
TNSN99203A1 (fr) 2005-11-10
SK5522001A3 (en) 2002-05-09
ZA200103322B (en) 2002-06-10
BR9914901A (pt) 2001-07-17
ID28291A (id) 2001-05-10
HUP0104696A3 (en) 2003-05-28
CA2348543A1 (en) 2000-05-11
NO20012013L (no) 2001-04-24
MA26702A1 (fr) 2004-12-20
TR200101174T2 (tr) 2001-10-22
US20010020036A1 (en) 2001-09-06

Similar Documents

Publication Publication Date Title
EA200100284A1 (ru) Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
DK0957914T4 (da) Formulering af 5-HT-agonister
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
ES8505519A1 (es) Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos.
EA200101019A1 (ru) Модуляторы рецепторов глюкокортикоидов
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
ES2196361T3 (es) Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
EA200401584A1 (ru) Способ содействия прекращению курения
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EA200400302A1 (ru) Способ лечения первичной бессонницы
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
EA200000693A1 (ru) Антагонисты хемокинного рецептора и способы их применения
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
CO5190678A1 (es) Terapia combinada para el tratamiento de la migrana
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
ECSP993183A (es) Agonistas de receptores 5- ht, y metoclopramida para el tratamiento de la migraña
ATE260118T1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
ES2116452T3 (es) Composiciones farmaceuticas que comprenden agonistas de receptores 5ht1 y potenciadores de la absorcion.
HN1999000180A (es) Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migra¥a.